William Blair Issues Optimistic Forecast for SPRY Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Stock analysts at William Blair lifted their Q4 2025 earnings per share (EPS) estimates for shares of ARS Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings per share of $0.05 for the quarter, up from their prior estimate of $0.02. William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.64) per share.

Other research analysts also recently issued research reports about the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 price target on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Raymond James raised ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $18.00 to $22.00 in a research note on Tuesday, August 13th. Finally, Leerink Partners increased their price target on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research note on Friday, September 20th. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, ARS Pharmaceuticals presently has an average rating of “Buy” and an average price target of $24.00.

ARS Pharmaceuticals Stock Down 0.7 %

SPRY stock opened at $14.01 on Friday. The business’s fifty day moving average is $14.63 and its 200-day moving average is $11.73. The company has a market cap of $1.36 billion, a P/E ratio of -27.47 and a beta of 0.90. ARS Pharmaceuticals has a twelve month low of $4.28 and a twelve month high of $18.51.

Insider Buying and Selling

In related news, insider Eric Karas sold 10,000 shares of the firm’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the sale, the insider now owns 5,693 shares of the company’s stock, valued at approximately $79,702. This trade represents a 63.72 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Richard E. Lowenthal sold 100,000 shares of the stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $12.93, for a total value of $1,293,000.00. Following the transaction, the chief executive officer now owns 1,398,499 shares of the company’s stock, valued at approximately $18,082,592.07. This trade represents a 6.67 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,584,351 shares of company stock valued at $24,152,378. 40.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On ARS Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. J.W. Cole Advisors Inc. increased its holdings in ARS Pharmaceuticals by 10.8% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock worth $131,000 after purchasing an additional 1,500 shares in the last quarter. nVerses Capital LLC bought a new position in ARS Pharmaceuticals during the 3rd quarter worth about $30,000. Creative Planning increased its holdings in ARS Pharmaceuticals by 7.0% during the 3rd quarter. Creative Planning now owns 35,263 shares of the company’s stock worth $511,000 after purchasing an additional 2,307 shares in the last quarter. Levin Capital Strategies L.P. increased its holdings in ARS Pharmaceuticals by 5.7% during the 1st quarter. Levin Capital Strategies L.P. now owns 55,250 shares of the company’s stock worth $565,000 after purchasing an additional 3,000 shares in the last quarter. Finally, HighTower Advisors LLC grew its holdings in shares of ARS Pharmaceuticals by 18.2% in the 3rd quarter. HighTower Advisors LLC now owns 28,310 shares of the company’s stock valued at $411,000 after acquiring an additional 4,369 shares in the last quarter. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.